Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist's perspective.

Abstract

Background/objectives: This article reviews some key emerging pharmacogenomic topics in oncology pharmacy practice.

Methods: Publications selected to review were mainly sourced from the new drug approvals by the Food and Drug Administration and the new regimens listed in the National Comprehensive Cancer Network.

Results: Key pharmacogenomic topics were presented, including genetic alterations influencing drug metabolism, drug efficacy, and changes in therapeutic targeting; Relevant clinical updates and advancements were summarized to provide an in-depth understanding.

Conclusion: The abundance of pharmacogenomic measures builds a solid foundation and heralds a paradigm shift toward individualized patient care.